{
    "clinical_study": {
        "@rank": "56964", 
        "arm_group": [
            {
                "arm_group_label": "gemigliptin only", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administrations of gemigliptin"
            }, 
            {
                "arm_group_label": "rosuvastatin only", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administrations of rosuvastatin"
            }, 
            {
                "arm_group_label": "gemigliptin and rosuvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administrations of gemigliptin and rosuvastatin"
            }
        ], 
        "brief_summary": {
            "textblock": "Investigate the pharmacokinetic drug interactions between gemigliptin and rosuvastatin in\n      healthy subjects"
        }, 
        "brief_title": "Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 20 to 45, healthy male subjects (at screening)\n\n          -  BMI between 18 - 27 kg/m2 (at screening)\n\n          -  Blood pressure SBP 90-140 mmHg, DBP 60-95 mmHg\n\n          -  FPG 70-125mg/dL glucose level (at screening)\n\n          -  Subject who totally understand the progress of this clinical trials, make decision by\n             his free will, and signed a consent form to follow the\n\n        Exclusion Criteria:\n\n          -  Subject who has past or present history of any diseases following below.(liver\n             including hepatitis virus carrier, kidney,\n             Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)\n\n          -  Subject who had GI tract disease that influencable to drug absorption or(ulcer, acute\n             or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)\n\n          -  Subject who had drug hypersensitivity reaction.(gemigliptin, rosuvastatin, aspirin,\n             antibiotics)\n\n          -  Subject who already admitted in other investigator product in 80 days\n\n          -  Subject who had whole blood donation in 60 days, or component blood donation in 30\n             days or transfusion in 30 days currently"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823133", 
            "org_study_id": "LG-GSCL001"
        }, 
        "intervention": [
            {
                "arm_group_label": "gemigliptin only", 
                "description": "gemigliptin 50mg qd on day 1~7", 
                "intervention_name": "gemigliptin only", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rosuvastatin only", 
                "description": "rosuvastatin 20mg qd on day 1~7", 
                "intervention_name": "rosuvastatin only", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "gemigliptin and rosuvastatin", 
                "description": "gemigliptin 50mg, rosuvastatin 20mg qd on day 1~7", 
                "intervention_name": "gemigliptin and rosuvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "to evaluate Cmax of gemigliptin and rosuvastatin at steady state", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hour post dose"
            }, 
            {
                "description": "to evaluate AUCt of gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin at steady state", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hour post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823133"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "to evaluate time of Cmax at steady state, gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hour post dose"
            }, 
            {
                "description": "to evaluate Cmin of gemigliptin and rosuvastatin at steady state", 
                "measure": "Cmin", 
                "safety_issue": "No", 
                "time_frame": "upto 72 hour post dose"
            }, 
            {
                "description": "to evaluate half-life of gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin", 
                "measure": "t1/2\u03b2", 
                "safety_issue": "No", 
                "time_frame": "upto 72 hour post dose"
            }, 
            {
                "description": "to evaluate Cmax of metabolite LC15-0636, N-desmethylrosuvastatin at steady state", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "upto 72 hour post dose"
            }, 
            {
                "description": "to evaluate AUC of metabolite LC15-0636, N-desmethylrosuvastatin at steady state", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "upto 72 hour post dose"
            }, 
            {
                "description": "to evaluate metabolic ratio of gemiglipin and rosuvastatin", 
                "measure": "metabolic ratio", 
                "safety_issue": "No", 
                "time_frame": "upto 72 hour post dose"
            }
        ], 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}